40.46
3.61%
1.41
Pre-market:
41.00
0.54
+1.33%
Harmony Biosciences Holdings Inc stock is traded at $40.46, with a volume of 840.35K.
It is up +3.61% in the last 24 hours and up +18.03% over the past month.
Harmony Biosciences Holdings Inc is a commercial-stage pharmaceutical company focused on developing and commercializing therapies for patients living with rare neurological diseases who have unmet medical needs. The company's product WAKIX (pitolisant), is a molecule with a novel mechanism of action specifically designed to increase histamine signaling in the brain by binding to H3 receptors and used for the treatment of cataplexy in adult patients with narcolepsy.
See More
Previous Close:
$39.05
Open:
$40
24h Volume:
840.35K
Relative Volume:
1.19
Market Cap:
$2.31B
Revenue:
$681.88M
Net Income/Loss:
$122.63M
P/E Ratio:
19.18
EPS:
2.11
Net Cash Flow:
$220.18M
1W Performance:
+11.09%
1M Performance:
+18.03%
6M Performance:
+26.28%
1Y Performance:
+27.80%
Harmony Biosciences Holdings Inc Stock (HRMY) Company Profile
Name
Harmony Biosciences Holdings Inc
Sector
Industry
Phone
(484) 539-9800
Address
630 W GERMANTOWN PIKE, PLYMOUTH MEETING
Compare HRMY with other stocks
Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
---|---|---|---|---|---|---|
HRMY
Harmony Biosciences Holdings Inc
|
40.46 | 2.31B | 681.88M | 122.63M | 220.18M | 2.11 |
VRTX
Vertex Pharmaceuticals Inc
|
427.89 | 110.19B | 10.63B | -479.80M | -1.35B | -1.99 |
REGN
Regeneron Pharmaceuticals Inc
|
687.80 | 75.58B | 13.85B | 4.65B | 3.32B | 40.41 |
ARGX
Argen X Se Adr
|
647.39 | 38.71B | 1.86B | -40.29M | -1.28B | -0.85 |
ALNY
Alnylam Pharmaceuticals Inc
|
264.99 | 34.18B | 2.09B | -332.26M | 16.06M | -2.62 |
BNTX
Biontech Se Adr
|
117.25 | 28.11B | 3.30B | -501.07M | 1.03B | -2.1146 |
Harmony Biosciences Holdings Inc Stock (HRMY) Upgrades & Downgrades
Date | Action | Analyst | Rating Change |
---|---|---|---|
Dec-17-24 | Initiated | H.C. Wainwright | Buy |
Oct-10-24 | Resumed | Raymond James | Outperform |
Sep-10-24 | Initiated | UBS | Buy |
Jun-21-24 | Initiated | Citigroup | Buy |
Jan-02-24 | Downgrade | BofA Securities | Neutral → Underperform |
Sep-25-23 | Downgrade | Goldman | Neutral → Sell |
Sep-07-23 | Initiated | Berenberg | Buy |
Apr-20-23 | Initiated | BofA Securities | Neutral |
Oct-14-22 | Upgrade | Janney | Neutral → Buy |
Oct-14-22 | Upgrade | Jefferies | Hold → Buy |
Aug-03-22 | Downgrade | Jefferies | Buy → Hold |
Jul-13-22 | Downgrade | Goldman | Buy → Neutral |
Jul-07-22 | Initiated | Mizuho | Buy |
Apr-14-22 | Initiated | Cantor Fitzgerald | Overweight |
Dec-01-21 | Initiated | Oppenheimer | Outperform |
Nov-04-21 | Initiated | Raymond James | Outperform |
Sep-23-21 | Initiated | Needham | Buy |
Mar-29-21 | Upgrade | Goldman | Neutral → Buy |
Sep-14-20 | Initiated | Goldman | Neutral |
Sep-14-20 | Initiated | Jefferies | Buy |
Sep-14-20 | Initiated | Piper Sandler | Overweight |
View All
Harmony Biosciences Holdings Inc Stock (HRMY) Latest News
Harmony Biosciences chief commercial officer sells shares worth $1.15m By Investing.com - Investing.com Canada
ARS Investment Partners LLC Invests $841,000 in Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) - MarketBeat
Should Value Investors Buy Harmony Biosciences (HRMY) Stock? - Yahoo Finance
Harmony Biosciences stock reaffirms buy rating ahead of Q4 results - MSN
What is HC Wainwright's Forecast for HRMY FY2029 Earnings? - MarketBeat
Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) Insider Jeffrey Dierks Sells 10,507 Shares - MarketBeat
HC Wainwright Reiterates "Buy" Rating for Harmony Biosciences (NASDAQ:HRMY) - MarketBeat
Harmony Biosciences stock reaffirms buy rating ahead of Q4 results By Investing.com - Investing.com Australia
H.C. Wainwright Reiterates Buy Rating on Harmony Biosciences Holdings Inc. (HRMY) - StreetInsider.com
Hennion & Walsh Asset Management Inc. Raises Stock Holdings in Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) - MarketBeat
Harmony Biosciences officer sells shares worth $388,840 By Investing.com - Investing.com Canada
Harmony Biosciences officer sells shares worth $388,840 - Investing.com
A Glimpse Into The Expert Outlook On Harmony Biosciences Through 7 Analysts - Benzinga
Harmony Biosciences chief commercial officer sells shares worth $265,946 By Investing.com - Investing.com South Africa
(HRMY) Trading Advice - Stock Traders Daily
Harmony Biosciences chief commercial officer sells shares worth $265,946 - Investing.com
How Much Upside is Left in Harmony Biosciences (HRMY)? Wall Street Analysts Think 39.48% - MSN
Why Harmony Biosciences (HRMY) Might be Well Poised for a Surge - MSN
Harmony Biosciences price target raised to $32 from $31 at BofA - Yahoo Finance
HRMY or RGEN: Which Is the Better Value Stock Right Now? - Yahoo Finance
JPMorgan Chase & Co. Purchases 93,622 Shares of Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) - MarketBeat
Harmony stock remains Outperform at Oppenheimer, guidance supports optimism By Investing.com - Investing.com Australia
Why Harmony Biosciences (HRMY) Is the Top Small Cap Stock to Buy with the Highest Upside Potential - Yahoo Finance
Harmony Biosciences (NASDAQ:HRMY) Shares Gap UpHere's What Happened - MarketBeat
Harmony Biosciences' (HRMY) "Buy" Rating Reaffirmed at Needham & Company LLC - MarketBeat
Harmony Biosciences Holdings Inc. (HRMY) PT Raised to $61 at Oppenheimer - StreetInsider.com
Harmony Biosciences reports strong revenue growth for WAKIX By Investing.com - Investing.com South Africa
Harmony Biosciences reports strong revenue growth for WAKIX - Investing.com India
Harmony Biosciences Projects Strong Revenue Growth for 2025 - TipRanks
Harmony Biosciences (HRMY) Reports Strong 2024 Revenues, Provides 2025 Revenue Guidance and Highlights Key Pipeline Catalysts - StreetInsider.com
Harmony Biosciences Revenue Surges 23% to $714M, Sets Ambitious $820M Target for 2025 - StockTitan
Top 10 Small Cap Stocks to Buy with the Highest Upside Potential - Insider Monkey
Top 5 US Stocks To Buy In January 2025 - Investing.com
HARMONY BIOSCIENCES TO PARTICIPATE IN PIPER SANDLER 35th ANNUAL HEALTHCARE CONFERENCE - GuruFocus.com
Principal Financial Group Inc. Cuts Stock Position in Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) - MarketBeat
Brokerages Set Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) Target Price at $49.80 - MarketBeat
HARMONY BIOSCIENCES TO PARTICIPATE IN OPPENHEIMER MOVERS IN RARE DISEASE SUMMIT - Kilgore News Herald
How the (HRMY) price action is used to our Advantage - Stock Traders Daily
Harmony Biosciences to Present at 43rd Annual J.P. Morgan Healthcare Conference - MSN
Harmony Biosciences (NASDAQ:HRMY) Trading Down 2.3%What's Next? - MarketBeat
Declining Stock and Solid Fundamentals: Is The Market Wrong About Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY)? - Simply Wall St
Research Analysts Offer Predictions for HRMY FY2024 Earnings - MarketBeat
State Street Corp Has $49.62 Million Stock Position in Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) - MarketBeat
Comprehensive Market Analysis of Latest Published 9 Rare Genetic Disorders Reports | DelveInsight - GlobeNewswire Inc.
HARMONY BIOSCIENCES TO PRESENT AT THE 43RD ANNUAL J.P. MORGAN HEALTHCARE CONFERENCE - BioSpace
HC Wainwright & Co. Initiates Coverage of Harmony Biosciences Holdings (HRMY) with Buy Recommendation - MSN
Harmony Biosciences (NASDAQ:HRMY) Shares Up 3.6%Here's Why - MarketBeat
Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) Sees Large Decrease in Short Interest - MarketBeat
Harmony Biosciences (NASDAQ:HRMY) Earns Buy Rating from Analysts at HC Wainwright - MarketBeat
Harmony Biosciences Holdings Inc Stock (HRMY) Financials Data
Revenue
Net Income
Cash Flow
EPS
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):